CONCORDBIO - Swing Trade Analysis

Last Updated Time : 02 Aug 25, 12:58 am

Swing Trade Rating: 4.2

📊 Analysis Summary

Concord Biotech (CONCORDBIO) shows signs of a potential short-term upswing, supported by strong quarterly earnings growth and a bullish MACD. While valuation is on the higher side, the stock is technically positioned near key moving averages and has zero debt, making it a promising swing trade candidate if momentum sustains.

🔍 Technical Indicators

RSI (47.3): Neutral — room to rise before overbought territory.

MACD (+16.4): Bullish — indicates upward momentum.

Price vs DMA

Current Price (₹1,833) is slightly above 50 DMA (₹1,825) and above 200 DMA (₹1,795) — positive trend.

Volume: Below average — needs confirmation via volume spike.

📈 Fundamental Snapshot

P/E (51.6) vs Industry PE (34.0): Overvalued — priced for growth.

PEG Ratio (1.75): Acceptable — growth justifies valuation.

ROE (22.3%) & ROCE (29.5%): Strong profitability.

EPS (₹35.5) vs Price (₹1,833): Slightly stretched.

Qtr Profit Growth (+47.8%): Excellent — strong earnings momentum.

FII & DII Holding ↓: Mild institutional selling — watch sentiment.

Debt to Equity (0.00): Debt-free — financial strength.

Dividend Yield (0.48%): Low — not a major factor for swing trading.

✅ Entry Strategy (If Not Holding)

Optimal Entry Price: ₹1,820–₹1,830 range, near 50 DMA.

Confirm entry with volume pickup and RSI crossing 50.

Watch for MACD divergence or bullish crossover continuation.

🚪 Exit Strategy (If Already Holding)

Exit near ₹1,950–₹2,000, where next resistance may lie.

If price drops below ₹1,790, consider stop-loss at ₹1,770 to limit downside.

⚖️ Final Verdict

Concord Biotech is a technically strengthening, fundamentally solid stock with strong earnings momentum and zero debt. While valuation is rich, the setup favors a short-term swing trade with moderate risk and attractive upside potential.

Edit in a page